ClinicalTrials.gg
CompletedNCT03595579ASCENDUpdated Sep 24, 2021Results posted

Assessing Symptomatic Clinical Episodes in Depression

A Phase 2 interventional study of AXS-05 and Bupropion in Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-09-24.

Sponsored by Axsome Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..

Enrollment
9th of 10
97 · median 320
Started
2018
the only one that year
Phase 2
4 of 10
none open now
Registered
2nd of 10
by date

Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 2, and was the 2nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., or all of them as a file.
02

Study summary

Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.

Read the detailed description

This study will evaluate the safety and efficacy of AXS-05 in a randomized, double-blind, active-controlled study in patients diagnosed with major depressive disorder (MDD) experiencing an acute episode.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • AXS-05
  • Major Depressive Disorder
  • MDD
  • Axsome
  • Depression
  • Dextromethorphan
  • Bupropion
  • Sigma-1
  • NDMA
  • ASCEND
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meets criteria for MDD
  • (BMI) between 18 and 40 kg/m\^2, inclusive
  • Agree to use adequate method of for the duration of the study
  • Additional criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Suicide risk
  • History of treatment resistance in current depressive episode
  • History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation or any experimental central nervous system treatment during the current episode or in the past 6 months
  • Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
  • Additional criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    AXS-05

    Drug: AXS-05

  • Active comparator
    Bupropion

    Drug: Bupropion

Interventions

  • DrugAXS-05

    AXS-05 taken twice daily for 6 weeks.

  • Bupropion taken twice daily for 6 weeks.

06

What researchers measure

Primary outcomes

  1. MADRS Score - Overall Change From Baseline

    The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.

    Time frame: Assessed at week 1, 2, 3, 4, 5 and 6 (averaged over the entire 6-week treatment period)

Other outcomes

  1. MADRS Score - Change From Baseline to Week 6

    The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.

    Time frame: 6 weeks

07

Results

Posted Sep 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneAXS-05Bupropion
Started4849
Mitt population4337
Safety population4848
Completed3835
Not completed1014

Outcome measures

PrimaryMADRS Score - Overall Change From Baseline

The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.

Time frame:
Assessed at week 1, 2, 3, 4, 5 and 6 (averaged over the entire 6-week treatment period)
Reported as:
Mean · score on a scale
MADRS Score - Overall Change From Baseline
score on a scaleAXS-05Bupropion
MADRS Score - Overall Change From Baseline13.7 ± 0.638.8 ± 0.68
Statistical analysis
  • AXS-05 vs Bupropion · Mixed Models Analysis · p = <.001
Other pre-specifiedMADRS Score - Change From Baseline to Week 6

The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.

Time frame:
6 weeks
Reported as:
Mean · score on a scale
MADRS Score - Change From Baseline to Week 6
score on a scaleAXS-05Bupropion
MADRS Score - Change From Baseline to Week 617.2 ± 1.412.1 ± 1.5
Statistical analysis
  • AXS-05 vs Bupropion · Mixed Models Analysis · p = 0.013

Adverse events

Collected over Adverse events were collected from the time of signing the ICF through 30 days after the last study visit or Early Termination (ET), whichever occurred first, an average of 11 weeks per participant.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AXS-050/48 (0%)0/48 (0%)35/48 (72.9%)
Bupropion0/48 (0%)0/48 (0%)30/48 (62.5%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAXS-05Bupropion
DizzinessNervous system disorders10/482/48
NauseaGastrointestinal disorders8/486/48
Dry mouthGastrointestinal disorders5/484/48
Decreased appetiteMetabolism and nutrition disorders5/484/48
HeadacheNervous system disorders4/485/48
AnxietyPsychiatric disorders5/481/48
ConstipationGastrointestinal disorders3/484/48
DiarrheaGastrointestinal disorders3/484/48
InsomniaPsychiatric disorders4/482/48
SedationNervous system disorders3/480/48

Baseline characteristics

Participants randomized

Age, Continuous
Age, Continuous(years)AXS-05BupropionTotal
Mean38.8 ± 11.9839.9 ± 12.9639.1 ± 12.34
Sex: Female, Male
Sex: Female, Male(Participants)AXS-05BupropionTotal
Female283260
Male201737
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AXS-05BupropionTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American151631
White322961
More than one race044
Unknown or Not Reported000
08

Study locations

4 sites
  • Clinical Research Site
    Beverly Hills, California 90210, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Bellevue, Washington 98007, United States
09

References and documents

Publications

  • Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022 Jul;179(7):490-499. doi: 10.1176/appi.ajp.21080800. Epub 2022 May 18. PubMed 35582785 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — via publication

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jan 2019, 7 months.

Results were first posted in Sep 2021, 2 years 8 months after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Jul 23, 2018
StartActual
May 30, 2018
Primary completionActual
Jan 7, 2019
CompletionActual
Jan 7, 2019
Results first posted
Sep 24, 2021
Last update
Sep 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03595579
Responsible party
Sponsor
First posted
Jul 23, 2018
Start date
May 30, 2018
Primary completion
Jan 7, 2019
Completion
Jan 7, 2019
Results posted
Sep 24, 2021
Last update
Sep 24, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion